Annals of internal medicine
-
Comment Randomized Controlled Trial
In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality.
Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10:327-36. 35123660.
-
Randomized Controlled Trial
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.
Frailty may modify the risk-benefit profile of certain treatments, and frail patients may have reduced tolerance to treatments. ⋯ AstraZeneca.
-
Despite increasing awareness of firearm-related deaths, evidence on the clinical and economic implications of nonfatal firearm injuries is limited. ⋯ National Institutes of Health.
-
The percentage of U.S. physicians who identify as being from an underrepresented racial or ethnic group remains low relative to their proportion in the U.S. population. How this percentage may have been affected by state bans on affirmative action in public postsecondary institutions has received relatively little attention. ⋯ None.
-
Yoshimura S, Sakai N, Yamagami H, et al. Endovascular therapy for acute stroke with a large ischemic region. N Engl J Med. 2022;386:1303-13. 35138767.